Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cyclosporin solution Clear all
Withdrawn Phase 4 Interventional

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Loteprednol etabonate, Artificial Tears, Restasis
Drug
Lead sponsor
Edward Holland, MD
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
CP-690,550, Cyclosporine, CP-690,550 Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 6, 2026, 4:37 AM EDT
Withdrawn Phase 4 Interventional

Tear Film Markers in Dry Eye Syndrome

NCT04515329
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine, Artificial tear
Drug
Lead sponsor
Vishal Jhanji
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

NCT01038167
View directory record Official record
Conditions
Hepatitis C
Interventions
telaprevir, cyclosporine, tacrolimus
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2010 · Synced Sep 6, 2026, 4:37 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface

NCT02199964
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

NCT07025811
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Vevye®, Xiidra®
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

NCT00256750
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004

NCT04523142
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
CyclASol Ophthalmic Solution
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Carmel, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax

NCT04555694
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine, Loteprednol Etabonate, Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert
Drug
Lead sponsor
Thomas Chester, OD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 6, 2026, 4:37 AM EDT
Recruiting Phase 4 Interventional

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

NCT07224529
View directory record Official record
Conditions
Meibomian Gland Dysfunction (MGD)
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 6, 2026, 4:37 AM EDT
No Longer Available No phase listed Expanded access

Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

NCT00633373
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
U.S. locations
8
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Sep 6, 2026, 4:37 AM EDT
Completed No phase listed Observational Results available

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

NCT00717418
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine ophthalmic emulsion 0.05%, artificial tears
Drug
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Wilson, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Eltrombopag, hATG, CsA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans

NCT01273207
View directory record Official record
Conditions
Bronchiolitis Obliterans, Constructive Bronchiolitis, Graft Versus Host Disease, Bronchiolitis, Exudative, Bronchiolitis, Proliferative, Graft-Versus-Host Disease
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

NCT00114777
View directory record Official record
Conditions
Renal Transplantation
Interventions
Cyclosporin A, Belatacept Less Intensive Regimen (LI), Belatacept More Intensive Regimen (MI)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 6, 2026, 4:37 AM EDT
Active, not recruiting Early Phase 1 Interventional

Intralesional Cyclosporine for Alopecia Areata

NCT07029204
View directory record Official record
Conditions
Alopecia Areata
Interventions
CycloSPORINE Injectable Product, Saline Solution
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

NCT00405431
View directory record Official record
Conditions
Glaucoma
Interventions
Restasis, Endura (artificial tears)
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

NCT05136170
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

NCT04342988
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cequa
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Laguna Hills, California • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
CsA high dose, CsA low dose, PA, Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

NCT04918823
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
Restasis
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

NCT03597139
View directory record Official record
Conditions
Dry Eye
Interventions
Voclosporin Ophthalmic Solution, Restasis®
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Garden Grove, California • Mission Hills, California • Rancho Cordova, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 6, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The COAT Trial: Cequa's Onset of Action Trial

NCT06482177
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine ophthalmic solution
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 6, 2026, 4:37 AM EDT